264P AMEERA-1: Subgroup analyses of phase I/II study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (aBC)

S Chandarlapaty,H.M Linden,P Neven,K Petrakova,A Bardia,P Kabos,S Braga,V Boni,V Pelekanou,N Ternès,A Gosselin,M Celanovic,P Cohen,G Paux,M Campone

doi:10.1016/j.annonc.2021.08.547

264P AMEERA-1: Subgroup analyses of phase I/II study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (aBC)

S Chandarlapaty, H.M Linden + Show 13 more

Open Access

PDF Available

https://doi.org/10.1016/j.annonc.2021.08.547

Copy DOI

Export

Save

Cite

Journal: Annals of Oncology	Publication Date: Sep 1, 2021
Citations: 3	License type: publisher-specific-oa

Affiliation: Memorial Sloan Kettering Cancer Center, Seattle Cancer Care Alliance, Universitair Ziekenhuis Leuven, Massachusetts General Hospital, University of Colorado Anschutz Medical Campus, University of Colorado Denver, Hospital Universitario HM Sanchinarro, HM Hospitales, Sanofi (United States), Sanofi (France), Institut de Cancérologie de l'Ouest

#Oral Selective Estrogen Receptor #Subgroup Analyses Of Phase #Antitumor Activity In Combination #Estrogen Receptor #Human Epidermal Growth Factor Receptor #Oral Selective Estrogen Receptor Degrader #Factor Receptor 2-negative Advanced Breast #Receptor 2-negative Advanced Breast Cancer #Growth Factor Receptor 2-negative Breast #Factor Receptor 2-negative Breast Cancer

Abstract
Full-Text PDF
Similar Papers

Abstract

Listen

Amcenestrant is an optimized, oral SERD that has shown favorable safety and encouraging antitumor activity in combination with palbociclib (palbo) in ER+/HER2– aBC. Here, we report updated data, including antitumor activity by subgroups.

Full Text

Published Version (Free)

View/Download pdf

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

264P AMEERA-1: Subgroup analyses of phase I/II study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (aBC)